High-dose chemotherapy with peripheral stem cell/autologous transplantation, treatment for multiple myeloma
Record ID 32006001573
English
Authors' objectives:
High-dose chemotherapy (HDC) involves administration of at least one anticancer drug in a dose that is planned to be sufficiently strong to completely eradicate residual myeloma cells in an attempt to reduce the risk of relapse. However, this approach destroys most marrow cells, suppressing the hematopoietic system. Autologous stem cell transplantation (autograft) involves harvesting stem cells from the bone marrow or peripheral blood of the patient during disease remission or best-treatment response and reinfusing these cells in order to aid hematopoietic recovery.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=2199
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Hematopoietic Stem Cell Transplantation
- Transplantation, Autologous
- Antineoplastic Combined Chemotherapy Protocols
- Multiple Myeloma
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.